Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

[1]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[2]  C. Qiu,et al.  The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects , 2015, The Journal of Immunology.

[3]  L. Rong,et al.  Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy. , 2014, Journal of theoretical biology.

[4]  M. Carrington,et al.  HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.

[5]  L. Weinberger,et al.  Stochastic variability in HIV affects viral eradication , 2014, Proceedings of the National Academy of Sciences.

[6]  John Frater,et al.  Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, ‘definetherain’ , 2014, Journal of virological methods.

[7]  J. Miro,et al.  Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression , 2014, AIDS.

[8]  R. Phillips,et al.  HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression , 2014, AIDS.

[9]  Mardge H. Cohen,et al.  Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals , 2014, AIDS.

[10]  James J. Goedert,et al.  Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.

[11]  J. Kappes,et al.  High-Multiplicity HIV-1 Infection and Neutralizing Antibody Evasion Mediated by the Macrophage-T Cell Virological Synapse , 2013, Journal of Virology.

[12]  P. Kaleebu,et al.  Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy , 2013, PloS one.

[13]  E. Shankar,et al.  Molecular signatures of T-cell inhibition in HIV-1 infection , 2013, Retrovirology.

[14]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[15]  Steve Kaye,et al.  Short-course antiretroviral therapy in primary HIV infection. , 2013, The New England journal of medicine.

[16]  B. Walker,et al.  HIV and HLA class I: an evolving relationship. , 2012, Immunity.

[17]  M. Rosińska,et al.  Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. , 2012, Archives of internal medicine.

[18]  C. Rouzioux,et al.  Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy , 2012, Antiviral therapy.

[19]  S. Lewin,et al.  Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells , 2011, Retrovirology.

[20]  Daniel Coombs,et al.  A Stochastic Model of Latently Infected Cell Reactivation and Viral Blip Generation in Treated HIV Patients , 2011, PLoS Comput. Biol..

[21]  T. Okazaki,et al.  PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice , 2011, The Journal of experimental medicine.

[22]  Jack T Stapleton,et al.  The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.

[23]  B. Berkhout,et al.  Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome , 2009, PloS one.

[24]  Jianqing J. Yu,et al.  Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. , 2009, Methods.

[25]  R. Kaul,et al.  Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection , 2008, The Journal of experimental medicine.

[26]  B. Berkhout,et al.  Highly Sensitive Methods Based on Seminested Real-Time Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 Unspliced and Multiply Spliced RNA and Proviral DNA , 2008, Journal of Clinical Microbiology.

[27]  Jacques Fellay,et al.  A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.

[28]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[29]  M. Friendly.  Corrgrams , 2002 .

[30]  T. Jaakkola,et al.  Fast optimal leaf ordering for hierarchical clustering , 2001, ISMB.

[31]  D. Ho,et al.  Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.

[32]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[33]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[34]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[35]  T. May.  An Evolving Relationship , 1990 .

[36]  David Heckerman,et al.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.

[37]  S. Hammer,et al.  Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. , 2003, The Journal of infectious diseases.